Please check your internet connection and try again.
# IV Dexamethasone
## Overview
Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. It is primarily used for its potent anti-inflammatory and immunosuppressive properties. It has a long biological half-life (36–54 hours).
## Primary Indications
* Cerebral edema (associated with brain tumors/neurosurgery)
* Severe allergic reactions and anaphylaxis
* Acute exacerbation of asthma/COPD
* Management of COVID-19 (in patients requiring supplemental oxygen)
* Antiemetic prophylaxis for chemotherapy (CINV)
* Anti-inflammatory treatment for croup (pediatric)
## Adult Dosing
* **Cerebral Edema:** Initial 10 mg IV, followed by 4 mg IM/IV every 6 hours.
* **COVID-19:** 6 mg IV daily for up to 10 days.
* **CINV Prophylaxis:** 8–20 mg IV as a single dose prior to chemotherapy.
* **Status Asthmaticus:** 4–12 mg IV as a single dose.
* **Allergic Reactions:** 4–20 mg IV as a single dose.
## Pediatric Dosing
* **Croup:** 0.6 mg/kg (max 10 mg) as a single dose IV/IM.
* **Cerebral Edema:** Load 1.5 mg/kg, followed by 1.5 mg/kg/day divided every 4–6 hours (max 16 mg/day).
* **Anti-inflammatory/Immunosuppression:** 0.08–0.3 mg/kg/day divided every 6–12 hours.
* *Note: Always verify pediatric dosing against local institutional weight-based protocols.*
## Dose Adjustments
* **Hepatic Impairment:** No specific criteria; however, clearance may be reduced. Monitor for clinical signs of excessive glucocorticoid effect.
* **Renal Impairment:** No adjustments typically required.
## Contraindications
* Systemic fungal infections.
* Known hypersensitivity to dexamethasone or components of the formulation.
* Administration of live or live-attenuated vaccines during high-dose therapy.
## Adverse Effects
* **Common:** Hyperglycemia, fluid retention, hypertension, insomnia, mood changes/agitation.
* **Serious:** GI ulceration/perforation, impaired wound healing, secondary infections (immunosuppression), adrenal suppression, and osteonecrosis.
## Key Drug Interactions
* **CYP3A4 Inducers:** (e.g., phenytoin, phenobarbital, rifampin) decrease dexamethasone efficacy.
* **CYP3A4 Inhibitors:** (e.g., ketoconazole, ritonavir) increase dexamethasone plasma concentrations.
* **NSAIDs/Aspirin:** Increased risk of GI ulceration and bleeding.
* **Antidiabetic Agents:** Dexamethasone may antagonize hypoglycemic effects, requiring dose adjustment of insulin/oral hypoglycemics.
## Monitoring
* **Blood Glucose:** Monitor closely, especially in patients with pre-existing diabetes.
* **Blood Pressure:** Monitor for new or worsening hypertension.
* **Electrolytes:** Monitor for hypokalemia, especially if on concurrent diuretics.
* **Neurological/Psychiatric:** Monitor for agitation, psychosis, or insomnia.
* **Clinical:** Observe sites of infection; monitor for GI bleed symptoms.
## Clinical Pearls
* **Abrupt Cessation:** Avoid abrupt withdrawal after prolonged therapy to prevent acute adrenal insufficiency; taper dose slowly.
* **Stability:** Dexamethasone phosphate is generally stable when diluted in D5W or NS; check compatibility before Y-site administration.
* **COVID-19 Evidence:** Dexamethasone provides mortality benefit specifically in COVID-19 patients requiring respiratory support (mechanical ventilation or oxygen); it is not indicated for mild cases not requiring supplemental oxygen.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify drug dosages, contraindications, and potential interactions against the most current institutional protocols and the manufacturer's official prescribing information (package insert) before clinical administration.
